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ABSTRACT
Despite great strides in pharmacotherapy for diabetes, there is increasing concern over
the risk of hypoglycemia in patients with diabetes receiving pharmacotherapy as they
become increasingly older. This has prompted the Japan Diabetes Society (JDS) to initiate
a survey on the current status of severe hypoglycemia in clinical settings. In July 2015, fol-
lowing approval from the JDS Scientific Survey/Research Ethics Committee, the JDS
extended an invitation to executive educators, who represented a total of 631 healthcare
facilities accredited by the JDS for diabetes education, to participate in the proposed sur-
vey. Of these, those who expressed their willingness to participate in the survey were sent
an application form required for obtaining ethical approval at these healthcare facilities
and were then asked, following approval, to enter relevant clinical data on an unlinked,
anonymous basis in a web-based registry. The current survey was fully funded by the JDS
Scientific Survey/Research Committee. A case registry (clinical case database) was launched
after facility-specific information (healthcare facility database) was collected from all partici-
pating facilities and after informed consent was obtained from all participating patients.
With severe hypoglycemia defined as the “presence of hypoglycemic symptoms requiring
assistance from another person to treat and preferably venous plasma glucose levels at
onset/diagnosis of disease or at presentation clearly less than 60 mg/dL (capillary whole
blood glucose, less than 50 mg/dL)”, the current survey was conducted between April 1,
2014 and March 31, 2015, during which facility-specific information was collected from a
total of 193 facilities with a total of 798 case reports collected from 113 facilities. Of the
193 respondent facilities, 149 reported having an emergency department as well, with the
median number of patients who required emergency transportation services to reach
these facilities totaling 4,962 annually, of which those with severe hypoglycemia
accounted for 0.34% (17). The respondent facilities accommodated a total of 2,237
patients with severe hypoglycemia annually, with the number of patients thus
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accommodated being 6.5 patients per site. A total of 1,171 patients were admitted for
severe hypoglycemia, with the number of patients thus admitted being 4.0 per site, who
accounted for 52.3% of all patients visiting annually for severe hypoglycemia. A review of
the 798 case reports collected during the survey revealed that 240, 480 and 78 patients
had type 1 diabetes, type 2 diabetes, and other types of diabetes, respectively; those with
type 2 diabetes were shown to be significantly older (median [interquartile range], 77.0
[68.0–83.0]) than those with type 1 diabetes (54.0 [41.0–67.0]) (P < 0.001); and the BMI
was shown to be significantly higher for those with type 2 diabetes (22.0 [19.5–24.8] kg/
m2) than for those with type 1 diabetes (21.3 [18.9–24.0] kg/m2) (P = 0.003). It was also
found that the median estimated glomerular filtration rate (eGFR) was significantly lower
among those with type 2 diabetes (50.6 mL [31.8–71.1]/min/1.73 m2) than among those
with type 1 diabetes (73.3 [53.5–91.1] mL/min/1.73 m2) (P < 0.001). Again, the median
HbA1c value at onset of severe hypoglycemia was shown to be 7.0 (6.3–8.1)% among all
patients examined, 7.5 (6.9–8.6)% among those with type 1 diabetes, and 6.8 (6.1–7.6)%
among those with type 2 diabetes, with the HbA1c value at onset of hypoglycemia being
significantly lower among those with type 2 diabetes (P < 0.001). Antecedent symptoms
of severe hypoglycemia were shown to be present, absent and unknown in 35.5, 35.6,
and 28.9% of all patients, respectively, with the incidence of symptomatic hypoglycemia
being significantly lower among those with type 1 diabetes (41.0%) than among those
with type 2 diabetes (56.9%). The antidiabetic agents used in those with type 2 diabetes
were insulin preparations (292 patients including 29 receiving concomitant sulfonylureas
[SUs]) (60.8%), SUs (159 insulin-na€ıve patients) (33.1%), and no insulin preparations or SUs
(29 patients) (6.0%). Of the 798 patients surveyed, 296 patients (37.2%) were shown to
have required emergency transportation services for severe hypoglycemia before. Thus,
the survey revealed, for the first time, the current status of treatment-related severe hypo-
glycemia in Japan and clearly highlights the acute need for implementing preventive
measures against hypoglycemia not only through education on hypoglycemia but
through optimization of antidiabetic therapy for those at high risk of severe hypoglycemia
or those with a history of severe hypoglycemia.
INTRODUCTION
According to a survey conducted in 2016 on the causes of
death among Japanese patients with diabetes mellitus (between
2001 and 2010), diabetic angiopathy accounted for 14.9% of all
causes, a far lower rate than that reported in an earlier survey
(26.8%; between 1991 and 2000)2,3. This survey also revealed
that the mean age at death was prolonged by 3.4 and 3.5 years,
respectively, among the male and female patients, compared to
that reported in the earlier survey2,3. These results appear to
reflect the ongoing successful implementation of diabetes treat-
ment and education in the country that focused on preventing
onset and/or progression of diabetic angiopathy in Japanese
patients with diabetes.
On the other hand, the ever-increasing number of elderly
patients with diabetes, weight gain, and severe hypoglycemia or
hypoglycemia unawareness are still among the major challenges
in current pharmacotherapy for diabetes. Indeed, increasingly
older patients with diabetes receiving antidiabetic therapy are
likely to be associated not only with impaired hepatic/renal
drug metabolism and/or poor medication adherence but also
with weight gain, which leads to poor glycemic control, thus
often constituting a vicious cycle necessitating the concurrent
use of multiple antidiabetic drugs. Again, current research sug-
gests that severe hypoglycemia or hypoglycemia unawareness is
among the factors promoting the onset and/or progression of
macroangiopathy or dementia4–6.
Against this background, the Japan Diabetes Society (JDS)
passed a resolution at its May 2013 Board of Directors meeting
initiating a survey on the status of treatment-related severe
hypoglycemia, which led to the JDS Committee for Surveys on
Severe Hypoglycemia being launched, with the authors of the
current report serving as principal members of the Committee.
METHODS
As per the survey plan prepared by the JDS Committee for
Surveys on Severe Hypoglycemia, the JDS extended an invita-
tion in July 2015 to executive educators, who represented a
total of 631 healthcare facilities accredited by the JDS for
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diabetes education, to participate in the proposed survey in
which severe hypoglycemia was defined as the “presence of
hypoglycemic symptoms requiring assistance from another per-
son to treat and preferably venous plasma glucose levels at
onset/diagnosis of disease or at presentation clearly less than
60 mg/dL (capillary whole blood glucose, less than 50 mg/dL)”.
The current survey was conducted between April 1, 2014 and
March 31, 2015, and facility-specific data collected from a total
of 193 facilities, as well as a total of 798 case reports collected
from 113 facilities, were included for analysis.
Healthcare facility survey
All participating facilities that reported having an emergency
department were inquired about the annual number of patients
who required emergency transportation services to reach these
facilities, as well as the proportion of those who did so for sev-
ere hypoglycemia.
Again, all participating facilities were inquired about the
number of patients with diabetes mellitus, type 1 and type 2
diabetes currently presenting to these facilities, the number of
patients with diabetes mellitus, type 1 and type 2 diabetes
receiving insulin formulations and/or sulfonylureas (SU), as well
as the annual number of patients presenting to or admitted to
these facilities for severe hypoglycemia. All these numbers were
analyzed as a whole and on a site-by-site basis.
Case-based survey
The data collected from the 798 patients using a uniform case
report form concerned the following items: (i) type of diabetes
and sex; (ii) age (years); (iii) duration of diabetes (years); (iv)
body mass index (BMI) (kg/m2); (v) estimated glomerular fil-
tration rate (eGFR) (mL/min/1.73 m2); (vi) glucose value at
presentation (before treatment) (mg/dL); (vii) HbA1c (%); (viii)
time-period of onset of severe hypoglycemia; (ix) severity of
diabetic microangiopathy; (x) presence or absence of antecedent
symptoms of hypoglycemia; (xi) presence or absence of serious
complications associated with severe hypoglycemia; (xii) prior
history of hypoglycemia requiring medical intervention; (xiii)
risk of traffic accidents due to hypoglycemia; and (xiv) factor(s)
judged by attending physician(s) to have affected the onset of
severe hypoglycemia.
As a first step, all reported patients were divided into those
with type 1 and type 2 diabetes to allow comparison of data
between the two groups. Then, all patients with type 2 diabetes
were grouped into those receiving insulin (insulin group includ-
ing those receiving both insulin and SUs), those receiving SUs
(SU group), and those not receiving insulin or SUs (non-insu-
lin/SU group) to allow comparisons between the three groups.
Distributions of variables used for analysis were expressed as
mean – standard deviation (SD) or median (interquartile range,
25th to 75th percentiles), and proportions (%). Statistical analy-
ses were performed by using IBM SPSS Statistics for Windows
version 20.0 (IBM Corp., Armonk, NY, USA), JMP 12 (SAS
Institute, Cary, NC, USA) or SPSS ver22. (Japan IBM, Tokyo,
Japan). The Pearson chi-square test was used to compare pro-
portions between the two groups and the Student/Welch t-test
and the Mann–Whitney U test was used to compare normally
and non-normally distributed means between the two groups,
respectively. The Kruskal–Wallis test was used to examine
whether the three groups were identical in distributions, and
the Bonferroni correction was used to test all detected differ-
ences for significance. A P value of <0.05 was considered to
indicate statistical significance.
Again, multiple logistic regression analysis was performed
to estimate the association between any of the patient attri-
butes or clinical symptoms and the presence or absence of
antecedent symptoms of hypoglycemia, as well as to explore
significant factors contributing to the absence of antecedent
symptoms of hypoglycemia. For each discrete (categorical)
variable, a reference category was defined, and all the other
categories were evaluated for their impact, against the refer-
ence category, on the absence of antecedent symptoms of
hypoglycemia by creating a set of dummy variables, and any
such impact was quantified in terms of odds ratios (OR) and
95% confidence intervals (CI) and tested for significance by
using the Wald’s test.
The proposed survey was implemented, and the survey
details disclosed, following approval from the JDS Scientific
Survey/Research Ethics Committee (JDSSSREC/H26-001, 27
November 2014), the JDS extended an invitation to prospective
participating facilities to participate in the proposed survey. Of
these, those who expressed their willingness to participate in
the survey were sent an application form required for obtaining
ethical approval for survey participation to ensure that ethical
approval was obtained at these facilities. All participating facili-
ties were then asked to submit all survey data to a web-based
registry (with patient data entered on an unlinked, anonymous
basis). The current survey was fully funded by the JDS Scien-
tific Survey/Research Committee.
RESULTS
Healthcare facility survey (Table 1)
(1) Number of patients presenting to the emergency depart-
ments at the respondent facilities
Of the 193 respondent facilities, a total of 149 facilities
(77.2%) reported having an emergency department. The
median number of emergency transportation services
ordered to reach these facilities totaled 4,962 per site annu-
ally; of these, those required for severe hypoglycemia
accounted for 17.0 (0.34%).
(2) Number of patients with diabetes mellitus receiving medical
services at the respondent facilities and the treatments
given to these patients
A total of 346,939 patients with diabetes mellitus were cur-
rently receiving medical services at the respondent facilities.
Of these, those with type 1 and type 2 diabetes accounted
for 6.2% and 87.9%, respectively. Again, of these, insulin
users (including those receiving other antidiabetic drugs as
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well) and SU users receiving no insulin accounted for
30.7% and 20.5%, respectively.
(3) Number of patients with diabetes mellitus presenting to/ad-
mitted to the respondent facilities for severe hypoglycemia
A total of 2,237 patients presented to the respondent facili-
ties for severe hypoglycemia annually, with the per-site
patient number being 6.5. Again, a total of 1,171 patients
were admitted to these facilities for severe hypoglycemia,
with the per-site patient number being 4.0; these patients
accounted for 52.3% of those presenting to these facilities
for hyperglycemia.
Case-based survey
(1) Survey results by type of diabetes
(i) Type of diabetes and sex: The respondent facilities
reported a total of 240 patients with type 1 diabetes
(males/females, 121/119), 480 patients with type 2 dia-
betes (males/females, 283/197) and 78 patients with
other types of diabetes (males/females, 60/18), and
those with type 1, type 2 and other types of diabetes
accounted for 30.1%, 60.2%, and 9.8%, respectively
(Table 2).
(ii) Patient age: The median age of all patients with dia-
betes mellitus was 71.5 (58.0–81.0) years old, with that
of those with type 1 and type 2 diabetes being 54.0
(41.0–67.0) and 77.0 (68.0–83.0) years old, respectively,
demonstrating that patients with type 2 diabetes were
significantly older than those with type 1 diabetes
(P < 0.001) (Tables 2 and 3; Figure 1a).
(iii) Duration of diabetes: The mean duration of diabetes
was 19.9 – 11.9 years in all patients with diabetes melli-
tus, with that in those with type 1 and type 2 diabetes
being 21.3 – 11.7 and 20.4 – 11.7 years, respectively,
showing no significant difference between the groups.
(iv) BMI: The median BMI of all patients with diabetes
mellitus, those with type 1 and type 2 diabetes was 21.6
(19.2–24.2), 21.3 (18.9–24.0) and 22.0 (19.5–24.8) kg/
m2, respectively, showing that BMI was significantly
higher for patients with type 2 diabetes than for all
patients with diabetes or those with type 1 diabetes
(P = 0.003) (Table 3).
(v) eGFR: Patients with type 1 and type 2 diabetes had a
median eGFR of 73.3 (53.5–91.1) and 50.6 (31.8–71.1)
mL/min/1.73 m2, respectively, showing that those with
type 2 diabetes had a significantly lower eGFR than
those with type 1 diabetes (P < 0.001) (Table 3).
(vi) The median glucose value at presentation (before
treatment) was 32.0 (24.0–40.0), 30.0 (22.0–40.0), and
32.0 (26.0–40.0) mg/dL for all patients with diabetes
mellitus, those with type 1 diabetes and those with
type 2 diabetes, respectively, with no significant differ-
ence shown between the groups (P = 0.15) (Tables 2
and 3).
(vii) The median HbA1c value at onset of severe hypo-
glycemia was 7.0 (6.3–8.1), 7.5 (6.9–8.6) and 6.8 (6.1–
7.6) for all patients with diabetes mellitus, those with
type 1 diabetes, and those with type 2 diabetes, respec-
tively, with the HbA1c value shown to be significantly
lower for those with type 2 diabetes (P < 0.001)
(Tables 2, 3; Figure 1b).
(viii) Time-period of onset of severe hypoglycemia: There
was no particular trend noted in time-period of onset
of severe hypoglycemia in all patients with diabetes
mellitus (Table 2).
(ix) Diabetic microangiopathy: Severe hypoglycemia was
noted in all patients, irrespective of the severity/progres-
sion of diabetic microangiopathy (Table 4).
(x) Presence or absence of antecedent symptoms of severe
hypoglycemia: Antecedent symptoms were shown to be
Table 1 | Healthcare facility survey
Number of patients presenting to the emergency departments at the respondent facilities (149 of the 193 facilities surveyed)
Number of emergency transportation services ordered per facility 4,962 (2073–9,910)
Number of emergency transportation services ordered for severe hypoglycemia per facility 17.0 (8.0–32.0)
Proportion of emergency transportation services ordered for severe hypoglycemia per facility 0.34%
Number of patients with diabetes mellitus receiving medical services at the respondent facilities and the treatments given to these patients
Number of patients regularly receiving medical services 346,939
Number (proportion) of patients with type 1 diabetes 20,553 (6.2%)
Number (proportion) of patients with type 2 diabetes 292,638 (87.9%)
Number (proportion) of insulin users (including those receiving other antidiabetic drugs) 106,645 (30.7%)
Number (proportion) of SU users without insulin 71,280 (20.5%)
Number of patients presenting to/admitted to the respondent facilities for severe hypoglycemia
Annual number of patients requiring medical services for severe hypoglycemia at these facilities 2,237
Number of patients requiring medical services for severe hypoglycemia per facility 6.5 (3.0–16.0)*
Annual number of patients admitted for severe hypoglycemia 1,171
Annual number of patients admitted for severe hypoglycemia per facility 4.0 (1.0–9.0)*
*Numbers, medians; numbers in parentheses, interquartile range (25th to 75th percentiles).
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present in 35.5%, absent in 35.6%, and unknown in
28.9% of all patients (Table 2), with the rate of their
occurrence being 41.0% and 56.9% in those with type 1
diabetes and those with type 2 diabetes, respectively,
showing that these symptoms occurred significantly less
frequently among those with type 1 diabetes than
among those with type 2 diabetes (P < 0.001)
(Table 3). The absence of antecedent symptoms, which
likely represented hypoglycemia unawareness, was asso-
ciated with lower glucose values at presentation (before
treatment) than their presence (30.0 [23.0–40.0] vs. 34.5
[27.5–43.0]), as well as a significantly higher prevalence
of diabetic peripheral neuropathy (71.0% vs. 61.1%;
P < 0.05) and diabetic autonomic neuropathy (59.7%
vs. 47.9%; P < 0.05) (Table 5a). Furthermore, using the
presence or absence of antecedent symptoms served as
the outcome variables and age, duration of diabetes,
HbA1c, glucose value at presentation (before treat-
ment), BMI, stage of nephropathy, type of diabetes, and
neuropathy as potential explanatory variables, logistic
regression analysis identified type 1 diabetes, low BMI
values, low glucose values at presentation (before treat-
ment), and the presence of peripheral neuropathy as
significant explanatory variables (Table 5b).
(xi) Presence or absence of serious complications associated
with severe hypoglycemia: Central nervous system
(CNS) sequelae were noted in 2.3% of all patients, 0.8%
of those with type 1 diabetes and 2.9% of those with
type 2 diabetes (Tables 2 and 3).
(xii) Prior history of hypoglycemia requiring medical inter-
vention: 37.2% of all patients with diabetes mellitus
reported having had hypoglycemia requiring medical
intervention, 44.5% reported having no such history,
and 18.3% reported being uncertain as to whether or
not they had any such history. Again, 67.8% of patients
with type 1 diabetes and 33.1% of patients with type 2
diabetes reported having visited their clinics again for
severe hypoglycemia, with significantly more patients
with type 1 diabetes shown to have visited their clinics
again for severe hypoglycemia (P < 0.001) (Tables 2
and 3).
(xiii) Risk of traffic accidents due to hypoglycemia:
1.9% of all patients with diabetes reported having
had traffic accidents or near-accidents, 71.1%
reported having had none, and 27.0 reported
being uncertain as to whether or not they had
done. Again, 4.9% of those with type 1 diabetes
and 1.3% of those with type 2 diabetes reported
having had done, with significantly more patients
with type 1 diabetes shown to have had done
(P = 0.023) (Tables 2 and 3).
(xiv) Factors judged by attending physicians to have affected
the onset of severe hypoglycemia included: inappropri-
ate diet or dietary timing (40%); drug overdose or




Type 1 diabetes, n (%) 240 (30.1%)
Type 2 diabetes, n (%) 480 (60.2%)
Other (including “unknown”), n (%) 78 (9.8%)
Sex (males/females), n (%) 464 (58.1%)/334
(41.9%)
Age (years), median (25th to 75th percentiles) 71.5 (58.0–81.0)
Duration of diabetes (years), mean – SD 19.9 – 11.9
BMI (kg/m2), median (25th to 75th percentiles) 21.6 (19.2–24.2)
eGFR (mL/min/1.73 m2), median (25th to 75th
percentiles)
58.4 (35.6–80.2)
Glucose value at presentation (before treatment),
median (25th to 75th percentiles)
32.0 (24.0–40.0)
HbA1c (%), median (25th to 75th percentiles) 7.0 (6.3–8.1)













Recovery from impaired consciousness, n (%)
Yes 780 (97.5)
CNS sequelae, n (%)
Present 18 (2.3)
Serious complications of severe hypoglycemia, n (%)
Absent 768 (97.5)
Present 30 (3.8)
















BMI, body mass index; CAD, coronary artery disease; CNS, central ner-
vous system; eGFR, estimated glomerular filtration rate; SD, standard
deviation.
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Table 3 | Comparison of factors associated with severe hypoglycemia by type of diabetes
Factor Type 1 diabetes (n = 240) Type 2 diabetes (n = 480) P-value
Age (years) 54.0 (41.0–67.0) 77.0 (68.0–83.0) <0.0001
Duration of diabetes (years) 21.3 – 11.7 20.4 – 11.7 0.344
BMI (kg/m2) 21.3 (18.9–24.0) 22.0 (19.5–24.8) 0.003
Glucose value at presentation (before treatment) (mg/dL) 30.0 (22.0–40.0) 32.0 (26.0–40.0) 0.15
HbA1c (%) 7.5 (6.9–8.6) 6.8 (6.1–7.6) <0.0001
Presence of antecedent symptoms (%) 41.0 56.9 <0.0001
Presence of CNS sequelae (%) 0.80 2.90 0.074
Proportion of patients presenting for severe hypoglycemia (%) 67.8 33.1 <0.0001
Total number of visits by patients with a history of prior visits (n) 3.0 (1.0–5.0) 1.0 (1.0–2.0) <0.0001
Proportion of patients experiencing traffic accidents or near-accidents 4.9 1.3 0.023
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Figure 1 | (a) Distribution of age in patients with severe hypoglycemia by type of diabetes. (b) Distribution of HbA1c values in patients with severe
hypoglycemia by type of diabetes.
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incorrect drug use (27%); sick days (11%); excessive
alcohol intake (8%); excessive exercise (4%); and others
(10%) (Figure 2).
(2) Comparison of factors associated with the onset of severe
hypoglycemia in patients with type 2 diabetes by their drug
use (Table 6)
The antidiabetic agents used in patients with type 2 dia-
betes included insulin preparations (292 patients including 29
receiving concomitant SUs; insulin group) (60.8%), SUs (159
insulin-na€ıve patients; SU group) (33.1%), and no insulin
preparations or SUs (29 patients; non-insulin/SU group)
(6.0%) (Figure 3). Patients in the insulin, SU and non-insu-
lin/SU groups had a median age of 74.0 (65.0–81.0), 81.0
(75.0–85.0), 77.0 (69.0–83.0) years, respectively, with those in
the SU and non-insulin/SU groups shown to be significantly
older than those in the insulin group (P < 0.001) (Table 6).
Patients 65 years old or older and those 75 years old or
older accounted for 76.4% and 47.3% of all patients in the
insulin group and 96.2% and 77.4% of all patients in the
SU group, respectively (Figure 4a). The patients in the insu-
lin, SU and non-insulin/SU groups had a median HbA1c
value of 7.2 (6.5–8.1), 6.4 (5.8–6.9), 6.0 (5.5–6.5)%, respec-
tively, with the HbA1c value shown to be significantly lower
for those in the SU and non-insulin/SU groups (P < 0.001)
(Table 6). A comparison of patients with low HbA1c values
showed that patients with HbA1c values 7% or lower and
7.5% or lower accounted for 46.8% and 63.6% of those in
the insulin group and 80.6% and 89.9% of those in the SU
group, respectively (Figure 4b).
Of all patients in the non-insulin/SU group, severe hypo-
glycemia was noted 7 patients receiving glinides (including 4
receiving DPP-4 inhibitors) and 8 glinide-na€ıve patients receiv-
ing DPP-4 inhibitors, who had a median age of 84.0 (81.0–
86.0) and 75.0 (71.0–81.0) years, a median HbA1c value of 6.5
(6.2–6.6) and 6.3 (5.8–6.4)%, and a median BMI of 21.2 (17.9–
24.2) and 22.4 (19.5–24.1) kg/m2, respectively. The remaining
14 patients in the non-insulin/SU group had a median age of
67.5 (60.0–78.0) years, a median HbA1c value of 5.5 (4.9–
5.8)%, and a median BMI value of 18.4 (17.1–21.6) with the
HbA1c and BMI values tending to be lower.
A review of the stages of nephropathy as well as the use of
insulin/SUs in all patients (Figure 5) showed that nephropathy
was far more advanced in those with type 2 diabetes than in
those with type 1 diabetes and that, among those with type 2
diabetes, there was no difference in stage of nephropathy
between the SU and insulin groups, with 50% of those receiv-
ing SUs shown to have ≥ stage 3 nephropathy.
DISCUSSION
The current survey sought to investigate the current status of
treatment-related severe hypoglycemia by inviting executive
educators, who represented 631 healthcare facilities accredited
by the JDS for diabetes education, to participate in the survey,
with severe hypoglycemia defined as the “presence of hypo-
glycemic symptoms requiring assistance from another person
to treat and preferably venous plasma glucose levels at onset/di-
agnosis of disease or at presentation clearly less than 60 mg/dL
(capillary whole blood glucose, less than 50 mg/dL)”.
Of the 631 facilities approached, a total of 193 facilities
responded with facility-specific information, thus making the
current survey on severe hypoglycemia utterly unprecedented
in scale in Japan. The median number of patients who required
emergency transportation services to reach these facilities
totaled 4,962 annually, of which those with severe hypoglycemia
accounted for 0.34% (Table 1). In contrast to the number of
emergency transportation services ordered for 2014 that totaled
some 5.4 million, according to the Statistics Bureau, Ministry of
Internal Affairs and Communications7, with the current survey
conducted in JDS-accredited healthcare facilities, our figure
(4,962 services) represented an estimate based on the reported
number of patients transported to emergency departments at
these facilities, which translated into an estimated total of some
20,000 patients transported annually for severe hypoglycemia in
Japan. Of note, of the roughly 346,939 patients enrolled in the
current survey, a total of 2,237 patients (0.64%) were shown to
have experienced severe hypoglycemia, which, coupled with the
reported number of diabetic patients receiving treatment that
totaled 3.166 million in the 2014 Ministry of Health, Labor and
Welfare survey8, again translated into an estimated total of
some 20,000 patients transported annually for severe hypo-
glycemia in Japan.
Table 4 | Severity/presence of complications in patients with diabetes
mellitus
Complication Stage No. of patients (%)
Nephropathy Stage 1 235 29.5
Stage 2 124 15.6
Stage 3 105 13.2
Stage 4 78 9.8
Stage 5 44 5.5
Unknown 211 26.5






Peripheral neuropathy Absent 147 18.4
Present 306 38.4
Unknown 344 43.2
Autonomic neuropathy Absent 175 22.0
Present 218 27.4
Unknown 403 50.6
NDR, non-diabetic retinopathy; PDR, proliferative diabetic retinopathy;
PPDR, pre-proliferative diabetic retinopathy; SDR, simple diabetic
retinopathy.
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Of all surveys on severe hypoglycemia available overseas, one
on all drug-associated adverse events including hypoglycemia at
58 emergency departments in the US is of particular note9,
which reported that a total of 42,585 patients had presented to
these emergency departments during the 2013–2014 period,
and 27.3% of these patients had been admitted. Of all drugs
used in these patients, anticoagulants were reported to be most
frequently associated with adverse events (17.6%), followed by
antibiotics (16.1%) and antidiabetic drugs (13.3%). Of these,
insulin and metformin were reported to be the second and
eighth most common cause of drug-related adverse events
(4,859 and 766 events, respectively). While SUs were not
among the top 15 common causes of these events, a review of
drug-associated adverse events in patients 65 years old or older
revealed that the SUs glipizide (not commercially available in
Japan), glibenclamide and glimepiride ranked eighth, four-
teenth, and fifteenth among the causes of drug-associated
adverse events. It was also found that insulin, oral hypo-
glycemic agents and other antidiabetic agents were the causes
of hospital admissions in 34.8%, 53.0%, and 38.5% of these
patients, respectively. Of note, while not readily available for
direct comparison, the proportion of hospital admissions
Table 5 | (a) Comparison between patients with awareness of antecedent symptoms and those without. (b) Logistic regression analysis of factors
predicting the absence of antecedent symptoms (n = 211)*
Parameter Awareness of antecedent symptoms P-value
Absent n Present n
(a)
Type of diabetes, type 1 (%)/type 2 (%) 111 (44.2)/140 (55.8) 251 77 (29.4)/185 (70.6) 262 <0.0001
Age at onset of severe hypoglycemia 70.0 (56.0–80.0) 283 70.0 (57.0–80.0) 282 0.565
Duration of diabetes (years) 19.0 (11.0–28.0) 243 20.0 (11.0–29.0) 233 0.815
BMI (kg/m2) 21.2 (18.9–24.1) 266 22.1 (19.9–24.7) 244 0.004
Glucose value at presentation (before treatment) 30.0 (23.0–40.0) 233 34.5 (27.5–43.0) 228 0.001
HbA1c at onset of severe hypoglycemia (%) 7.2 (6.5–8.3) 255 7.2 (6.5–8.1) 239 0.615
Serum creatinine at onset of severe hypoglycemia (mg/dL) 0.9 (0.7–1.4) 261 0.9 (0.7–1.4) 264 0.365
eGFR at onset of severe hypoglycemia (mL/min/1.73 m2) 59.7 (36.2–80.4) 261 58.1 (35.3–79.1) 264 0.608
Peripheral neuropathy, present 141 (71.0%) 200 99 (61.1%) 162 0.047
Autonomic neuropathy, present 108 (59.7%) 181 67 (47.9%) 140 0.035
Factor Odds ratio 95% confidence interval P-value
Lower limit Upper limit
(b)
Age at onset of severe hypoglycemia 1.012 0.988 1.037 0.320
Duration of diabetes 0.975 0.944 1.008 0.139
HbA1c at onset of severe hypoglycemia 0.873 0.679 1.123 0.291
Glucose value at presentation (before treatment) 0.967 0.944 0.991 0.006
BMI 0.884 0.813 0.962 0.004
Stage of nephropathy 0.447
Stage 1 Reference value
Stage 2 0.763 0.321 1.811 0.539
Stage 3 1.998 0.748 5.339 0.168
Stage 4 0.883 0.245 3.173 0.848
Stage 5 0.934 0.247 3.538 0.920
Type of diabetes
Type 1 Reference value
Type 2 0.374 0.159 0.880 0.024
Peripheral neuropathy
Absent Reference value
Present 3.191 1.265 8.052 0.014
Autonomic neuropathy
Absent Reference value
Present 1.336 0.562 3.176 0.511
BMI, body mass index; eGFR, estimated glomerular filtration rate. *Patients with no missing data for any of the parameters compared (those with
no antecedent symptoms, n = 119; those with antecedent symptoms, n = 92).
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accounted for by oral hypoglycemic agents reported in the US
(53.0%) appears to be nearly consistent with that for severe
hypoglycemia reported in the current survey (52.3%).
Another report from the US is also of interest, in that it
demonstrated the status of insulin-associated adverse events
resulting in visits to emergency departments on a nationwide
basis by drawing on data from a total of 8,100 patients present-
ing to these departments for such reasons as insulin-associated
hypoglycemia, insulin product name confusion, and insulin
overdose, reporting that a total of 97,648 patients had presented
to emergency departments for these reasons annually, with
29.3% of these patients shown to have been admitted, 60.6%
shown to be associated with serious neurological symptoms,
and 53.4% shown to have an estimated glucose value of
50 mg/dL or lower10.
Conventionally, the diagnosis of hypoglycemia is generally
assumed to be consistent with glucose values less than 70 mg/
dL11. Of note, a joint position statement of the American Dia-
betes Association and the European Association for the Study
of Diabetes in 2016 recommended that “criteria used in clinical
studies for hypoglycemia should include self-monitoring of
whole blood glucose as converted to venous plasma glucose,
interstitial glucose concentration in continuous glucose moni-
toring or venous plasma glucose values less than 54 mg/dL,
which do not occur under physiological conditions in non-dia-
betic individuals and serious hypoglycemia resulting in
impaired consciousness and requiring the assistance of another
to treat”12. In this survey, which focused on treatment-
associated severe hypoglycemia, however, severe hypoglycemia
was defined as preferably venous plasma glucose levels at
onset/diagnosis of disease or at presentation clearly less than
60 mg/dL (capillary whole blood glucose, less than 50 mg/dL),
with priority given to the supposed presence of symptoms of
hypoglycemia not amenable to self-management in affected
patients. Indeed, given that patients with glucose values 60 mg/
dL or higher accounted for 3.9% of both type 1 and type 2 dia-
betic patients, suggesting that severe hypoglycemia may not be
diagnosed on the basis of glucose values alone, the diagnostic
approach to severe hypoglycemia in this study which involved
assessment of both glucose values and symptoms appears to be
valid.
Risk factors for severe hypoglycemia are reported to include
type of diabetes13, aging14, SUs15,16, insulin therapy10,13,17, low
HbA1c values16,18, and long duration of diabetes13,14. In this
survey as well, severe hypoglycemia was noted in as many as
30% of patients with type 1 diabetes who accounted for 6.2%
of all patients with diabetes mellitus presenting to outpatient
clinics (Tables 1 and 2). Indeed, severe hypoglycemia was noted
in type 1 diabetic patients across all age brackets but was noted
frequently in type 2 diabetic patients with their median age
being 77.0 years and 83.4% of these patients being 65 years old














Figure 2 | Factors affecting the onset of severe hypoglycemia.
Table 6 | Comparison of factors associated with severe hypoglycemia by drug use
Parameter Insulin group (n = 292) SU group (n = 159) Non-insulin/SU group (n = 29)
Age (years) 74.0 (65.0–81.0) 81.0 (75.0–85.0)*** 77.0 (69.0–83.0)***
HbA1c (%) 7.2 (6.5–8.1) 6.4 (5.8–6.9)** 6.0 (5.5–6.5)***
Glucose value at presentation (before treatment) 32.0 (25.0–41.0) 33.0 (27.0–38.0) 31.5 (23.5–42.0)
eGFR (mL/min/1.73 m2) 55.9 (36.1–75.4) 42.3 (29.9–59.9)*** 39.5 (14.4–70.3)
BMI (kg/m2) 22.7 (19.6–25.2) 22.7 (19.7–24.8) 20.6 (18.1–23.8)















Figure 3 | Causal agents of severe hypoglycemia in type 2 diabetic
patients.
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hypoglycemia was shown to be significantly lower in type 2
diabetic patients than in type 1 diabetic patients, and those with
HbA1c 7% or lower and 7.5% or lower accounted for 59.8%
and 73.4%, respectively, of all type 2 diabetic patients, as well
as 31.8% and 50.0%, respectively, of all type 1 diabetic patients.
Again, severe hypoglycemia was shown to have occurred fre-
quently in type 1 diabetic patients, including those with HbA1c
values 9% or higher (Figure 1b). It was also found that the dis-
tributions of age and HbA1c values varied depending on the
type of diabetes.
Of the antidiabetic drugs used in type 2 diabetic patients,
insulin was shown to be most commonly used (60.8%) fol-
lowed by SUs (33.1%), which, together, accounted for 94% of
all drugs used (Figure 3). Of note, Iwakura and colleagues
examined a total 135 type 2 diabetic patients transported to
their emergency department for severe hypoglycemia over a 3-
year period starting in 2008 and reported that the use of SUs
was a far more common cause of severe hypoglycemia than
insulin therapy, thus highlighting concern over severe hypo-
glycemia associated with SUs19. By the same token, by 2010,
there emerged concern over severe hypoglycemia associated
with combined use of SUs and DPP-4 inhibitors, which
prompted the JDS to issue precautions for use of SUs com-
bined with DPP-4 inhibitors20. In this regard, the current 1-
year survey (started in 2014) showed that more patients were








Insulin users (n = 292) SU users (n = 159)
Insulin users (n = 250) SU users (n = 129)
74.0 (65.0-81.0)
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Figure 4 | (a) Distribution of age in type 2 diabetic patients by drug use. (b) Distribution of HbA1c values in type 2 diabetic patients.
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SUs has come under scrutiny in recent years. On the other
hand, consistently with earlier reports, this survey also revealed
that SU users were older and had lower HbA1c values than
insulin users, suggesting that, when using SUs in diabetic
patients, adequate care needs to be exercised to ensure that the
glycemic control goals set for these patients are not too low,
while taking their age into account. In this survey, patients
65 years old or older and 75 years old or older accounted for
76.4 and 47.3%, respectively, of those receiving insulin and 96.2
and 77.4%, respectively, of those receiving SUs (Figure 4a).
Again, patients with HbA1c values 7.0% or lower and 7.5% or
lower accounted for 46.8 and 63.6%, respectively, of those
receiving insulin and 80.6 and 89.9%, respectively, of those
receiving SUs (Figure 4b). The current survey results also
appear to support the glucose (HbA1c) control goals for elderly
patients with diabetes mellitus proposed by the JDS/Japan Geri-
atrics Society in 2016, which recommended that the lower
HbA1c limit should range between 6.5 and 7.5% depending on
the degree of cognitive and ADL impairment in elderly
patients21. Of note, however, insulin users and SU users were
shown to vary with regard to their age and HbA1c distributions
in this survey, suggesting that insulin and SU users need to be
addressed separately and their glycemic control goals need to
be established separately rather than uniformly. Again, given
that patients receiving glinides, DPP-4 inhibitors and no antidi-
abetic drugs accounted for 1.5, 1.7, and 2.5%, respectively, of all
non-insulin/SU users, who, in turn, accounted for 6% of all
patients with severe hypoglycemia in this survey (Figure 3), it
remains a challenge to elucidate the causal relationship between
these insulin-promoting drugs and the onset of severe hypo-
glycemia. Further in-depth analysis is required to clarify
whether or not undernutrition may have contributed to the
BMI and HbA1c values in non-insulin/SU users that tended to
be lower.
In this survey, renal function (eGFR) was shown to be
decreased in type 2 diabetic patients to a greater degree than
that in type 1 diabetic patients, and many of these patients
were shown to have never presented to their clinics for hyper-
glycemia before (Table 3). Half of type 2 diabetic patients
receiving SUs were shown to be in ≥ stage 3 nephropathy, thus
highlighting the need for appropriate use of SUs in these
patients, given that SUs are to be used judiciously or con-
traindicated depending on the progression of nephropathy (Fig-
ure 5). In this regard, this survey did investigate the types of
SUs used but fell short of determining the impact of SUs by
type on the onset of severe hypoglycemia as it related to renal
function, given the lack of back ground information on their
frequency of use.
According to a diabetes case registry launched by diabetolo-
gists in Japan, Japanese patients with type 2 diabetes are
reported to have a mean age of approximately 65 years, a mean
BMI value of approximately 25 kg/m2, and a mean HbA1c
value of 7.1%22. Compared to these typical patients, those type
2 diabetic patients who were shown to have been associated
with severe hypoglycemia in this survey were clearly older, had
lower BMI values, and slightly lower HbA1c values; given that
nearly all of these patients were being treated with insulin or
SUs, many of these patients were thought to be non-obese
patients with impaired endogenous insulin secretion. Also,
elderly type 2 diabetic patients with low BMI values were
thought to include those with frailty- or sarcopenia-associated
weight loss. In this regard, research suggests that ultra-rapid-
acting insulin is likely to be rapidly absorbed in insulin patients
with low BMI values, thus potentially placing these patients at
high risk of postprandial hypoglycemia23. Furthermore, it was
also suggested in this survey that renal impairment associated
with aging and prolonged duration of diabetes is likely to lead
to the pharmacological action of SUs being chronically
Type 2 (SU useres)
Type 2 (insulin useres)
Type 1 (insulin useres)
0% 20% 40% 60% 80% 100%
P = 0.159
28 24 22 25 5
70
118 35 32 5 24
64 49 37 10
P = 0.004
P<0.001*
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Figure 5 | Proportion of stages of nephropathy among patients with diabetes mellitus by type of diabetes comparisons using the Bonferroni
correction. All P-values with the chi-square test for comparisons between patients with stage 1 to 2 and those with stages 3 to 5. *Refers to
combinations shown to be significant at an alpha level of 0.05 in multiple comparisons using the Bonferroni correction.
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enhanced, thus contributing not only to decreases in HbA1c
but to the worsening of hypoglycemia in SU users.
Thus, given the ever-increasing population of elderly patients
with type 2 diabetes, it appears imperative that care be exer-
cised in reviewing their current treatment regimens, as well as
in optimizing education for these patients, whether or not they
have a history of severe hypoglycemia, with consideration also
given to their age, HbA1c value, renal function or their use of
insulin or insulin secretion-promoting agents.
Of all factors examined in the survey for association with the
onset of severe hypoglycemia, inappropriate diet or dietary tim-
ing, excessive alcohol intake, sick days were found to be associ-
ated with the onset of severe hypoglycemia in the majority of
patients, in addition to factors associated with human errors,
such as drug misuse or drug name confusion, which were
shown to be associated with the onset of severe hypoglycemia
in some (Figure 2). It was also found, however, that severe
hypoglycemia could be avoided through appropriate treatment
choice and patient education in a majority of cases. Of note,
the Dose Adjustment for Normal Eating—Hypoglycemia
Awareness Restoration Training (DAFNE-HART) study24
reported that no episodes of severe hypoglycemia were noted,
with decreased episodes of moderate hypoglycemia, in type 1
diabetic patients with reduced awareness of hypoglycemia for 1
year after they were provided with a basic knowledge of hypo-
glycemia, its symptomatic diversity, and patient-specific hall-
mark features of its symptoms, as well as instructions on how
to deal with hypoglycemia. This appears to suggest an acute
need to establish in Japan a similar approach to instructing
patients or generating patient educational material on how to
prevent hypoglycemia to that used in this study.
Antecedent symptoms of severe hypoglycemia were noted in
41.0% of patients with type 1 diabetes and 56.9% of patients
with type 2 diabetic patients in this survey (Table 3). Thus,
those with hypoglycemia unawareness as no antecedent symp-
toms of severe hypoglycemia accounted for a high proportion
of both type 1 and type 2 diabetic patients (59.0 and 43.1%,
respectively), suggesting that hypoglycemia unawareness is likely
an important background factor for severe hypoglycemia. In
this regard, Geddes and colleagues reported that hypoglycemia
unawareness is noted in 19.5% of all patients with type 1 dia-
betes, with their risk for onset of severe hypoglycemia increased
by 6-fold25. It is also reported that hypoglycemia unawareness
is noted in 9.8% of type 2 diabetic patients receiving insulin
therapy as well, with their risk for onset of severe hypoglycemia
increased by 17-fold26. Of note, hypoglycemia unawareness is
assumed to represent an adaptive response to hypoglycemia to
protect the brain against its recurrent episodes and thus a
decrease in the threshold for counterregulatory response to
hypoglycemia27. In this survey, the glucose level at onset of sev-
ere hypoglycemia (before treatment) was shown to be low in
patients without antecedent symptoms of hypoglycemia, likely
reflecting a decrease in the threshold for glycemic response
resulting in an associated decrease in hyperglycemic response.
Again, in our survey, type 1 diabetes, low BMI value and
peripheral neuropathy were identified as further factors associ-
ated with hypoglycemia unawareness (Table 5B). Given that
low BMI value was identified as a factor associated with hypo-
glycemia unawareness in the survey, partly because type 1 dia-
betic patients tend to have low BMI values but also because
type 2 diabetic patients with low BMI values are thought likely
to be associated with worsening of hypoglycemia, further
detailed study is required to clarify the association between
BMI, worsening of hypoglycemia, and hypoglycemia unaware-
ness. Again, while the association between neuropathy and
asymptomatic hypoglycemia remains controversial28,29, our sur-
vey results demonstrated that peripheral neuropathy is more
strongly associated with asymptomatic hypoglycemia than auto-
nomic neuropathy or autonomic failure. Since our survey
employed no consistent or quantitative criteria for diagnosis of
autonomic neuropathy, peripheral neuropathy, a factor that is
readily amenable to early diagnosis in clinical settings, was cho-
sen as an explanatory factor for asymptomatic hypoglycemia.
Severe hypoglycemia is shown to lead to CNS sequelae in
some patients with impaired consciousness. In this survey as
well, these CNS sequelae were noted in 18 of 798 patients, with
cognitive decline also noted in 8 of these patients, thus high-
lighting the fact that these sequelae are among the most fre-
quent of complications associated with severe hypoglycemia
(Table 2). Indeed, it is reported that severe hypoglycemia is also
associated with cognitive decline in elderly patients with dia-
betes mellitus5, and that the more frequent the onset of severe
hypoglycemia in elderly patients with diabetes mellitus, the
greater their future risk for dementia30. Thus, given that severe
hypoglycemia is shown to be common in elderly patients with
diabetes mellitus, further study is acutely required in a large
population of elderly patients to examine in depth the impact
of severe hypoglycemia on their cognitive function and CNS
symptoms as well as to establish countermeasures against severe
hypoglycemia, including preventive measures. Again, severe
hypoglycemia is shown to be associated with arrhythmia, coro-
nary artery disease (CAD) and mortality31–33. In this regard,
while eleven deaths were reported in the current survey
(Table 2), arrhythmia and CAD was reported in as few as 1
patient each. However, the retrospective nature of the survey
involving a limited number of patients made it rather difficult
to establish any association between the direct causes of death
and arrhythmia or CAD.
Prior history of severe hypoglycemia and low HbA1c values
are known to be associated with increased risk for traffic acci-
dents34. Therefore, the current survey investigated traffic acci-
dents or near-accidents in patients with severe hypoglycemia
and demonstrated, while being not a patient self-administered
but physician-mediated survey, that 15 patients reported having
had traffic accidents or near-accidents (Table 2). Given that the
survey questionnaire featured “near-accidents” alongside “traffic
accidents” as a single answer choice, our figure may suggest
that traffic accidents due to severe hypoglycemia occur less
ª 2018 Japan Diabetes Society (JDS). Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol. 9 No. 3 May 2018 653
S P E C I A L R E P O R T
http://onlinelibrary.wiley.com/journal/jdi Status of treatment-related severe hypoglycemia in Japanese patients with diabetes
frequently than assumed but the fact remains that traffic acci-
dents lead to enormous social losses. Thus, the survey results
appear to point to the need for instructing patients at high risk
of severe hypoglycemia, particularly those with hypoglycemia
unawareness on how to prevent or deal with hypoglycemic epi-
sodes occurring while driving.
The limitations of the current survey were that it was pri-
marily directed at healthcare facilities accredited by the JDS
for diabetes education where diabetologists were available and
that it only involved 193 of the 631 facilities approached
(30.5%) and a total of 798 patients reported from 113 of the
193 respondent facilities. Furthermore, the survey results on
severe hypoglycemia may not necessarily reflect those in rou-
tine diabetes care, where patients with type 2 diabetes are
usually being cared for by their family physicians. Again,
diagnostic accuracy may have suffered for awareness of ante-
cedent symptoms, complications such as neuropathy or
retinopathy, and impact of severe hypoglycemia on cognitive
function, in this retrospective, physician-mediated question-
naire survey. Despite these limitations, this first multicenter
survey may have much to offer, in that it provided insights
into the current status of severe hypoglycemia, its social
impact, and background factors, thus highlighting issues of
current interest in diabetes treatment in Japan, while exten-
sive and detailed studies are required to build on the find-
ings reported.
In conclusion, the survey revealed, for the first time, the cur-
rent status of treatment-related severe hypoglycemia in Japan
and demonstrated that patients with severe hypoglycemia
accounted for 0.34% of all patients requiring emergency trans-
portation services to reach emergency departments; that, of
these, type 1 and type 2 diabetic patients accounted for approx-
imately 30 and 60%, respectively; that severe hypoglycemia
occurred in type 1 diabetic patients across a relatively wide age
range, while, in contrast, it occurred frequently in elderly type 2
diabetic patients with reduced renal function and low HbA1c
values, the majority of whom were receiving insulin or SUs.
Again, the survey revealed that severe hypoglycemia was associ-
ated with dementia, CNS sequelae and even deaths, thus high-
lighting the acute need for implementing preventive measures
against hypoglycemia not only through education on hypo-
glycemia but through optimization of antidiabetic therapy for
those at high risk of severe hypoglycemia or those with a his-
tory of severe hypoglycemia.
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Table S1 | Participated physicians at the JDS-accredited educational facilities.
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